| Effect of daily hormone therapy and alendronate use on bone mineral density in postmenopausal women. | |
| | |
MedLine Citation:
|
PMID: 12969694 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To evaluate the effect of daily oral and transdermal hormone therapy alone or in combination with alendronate on bone mineral density in postmenopausal women. DESIGN: Comparative prospective clinical study. SETTING: Outpatient clinic of a training and research hospital. PATIENT(S): One hundred seventy-three consecutive postmenopausal women with no previous hormone therapy and a bone mineral density T score <-1 SD were randomly enrolled. INTERVENTION(S): Oral conjugated estrogen, alone or with alendronate, or transdermal estrogen, alone or with alendronate, given for 1 year. All patients also received medroxyprogesterone acetate and calcium. MAIN OUTCOME MEASURE(S): Bone density measurement at L2 to 4 region by dual-energy X-ray absorptiometry. RESULTS: At the end of 1 year, significant increase in bone density measurements were seen in all groups. Oral conjugated estrogen and transdermal estrogen have the same effect on bone mineral density loss. Hormone therapy alone stabilized the bone mineral density loss. Hormone therapy together with alendronate resulted in better values in all groups. CONCLUSION: Hormone therapy is adequate in osteopenic women. However, hormone therapy plus alendronate is advantageous in women with considerable bone mineral density loss. |
| | |
Authors:
|
Inci Davas; Aysun Altintas; Tevfik Yoldemir; Ahmet Varolan; Ali Yazgan; Basak Baksu |
Related Documents
:
|
12176784 - Biological activity of anastrozole in postmenopausal patients with advanced breast canc... 6408874 - Primary plasma cell leukaemia. a case report and a review of the literature. 15300364 - Idiopathic osteoporosis in premenopausal women. 12957264 - Plasma flt-3 ligand concentration correlated with radiation-induced bone marrow damage ... 9647154 - Shedding of syncytiotrophoblast microvilli into the maternal circulation in pre-eclampt... 23105804 - Estimation of plasma haemoglobin by a modified kinetic method using o-tolidine. |
Publication Detail:
|
Type: Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Fertility and sterility Volume: 80 ISSN: 0015-0282 ISO Abbreviation: Fertil. Steril. Publication Date: 2003 Sep |
Date Detail:
|
Created Date: 2003-09-12 Completed Date: 2003-10-17 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 0372772 Medline TA: Fertil Steril Country: United States |
Other Details:
|
Languages: eng Pagination: 536-40 Citation Subset: IM |
Affiliation:
|
Second Obstetrics and Gynecology Clinic, Sişli Etfal Training and Research Hospital, Istanbul, Turkey. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Absorptiometry, Photon Administration, Cutaneous Administration, Oral Alendronate / administration & dosage* Bone Density / drug effects* Calcium / therapeutic use Drug Administration Schedule Drug Therapy, Combination Estrogen Replacement Therapy* Estrogens, Conjugated (USP) / administration & dosage Female Humans Medroxyprogesterone Acetate / administration & dosage Middle Aged Osteoporosis, Postmenopausal / drug therapy*, metabolism Postmenopause* Progesterone Congeners / administration & dosage |
| Chemical | |
Reg. No./Substance:
|
0/Estrogens, Conjugated (USP); 0/Progesterone Congeners; 66376-36-1/Alendronate; 71-58-9/Medroxyprogesterone Acetate; 7440-70-2/Calcium |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Oxidative stress is associated with increased apoptosis leading to spermatozoa DNA damage in patient...
Next Document: Effects of hormone therapy and alendronate on C-reactive protein, E-selectin, and sex hormone-bindin...